The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Abstract
BACKGROUND: Second-generation antipsychotics have largely replaced first-generation antipsychotics for the treatment of schizophrenia, but a large-scale cost/effectiveness analysis has not been attempted. METHOD: Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months. Patients with tardive dyskinesia were prohibited from assignment to perphenazine. Patients could be reassigned at any time to another second-generation drug, including clozapine, but not to perphenazine. The cost analysis included medications plus health services use. Quality-adjusted life year (QALY) ratings were assessed on the basis of Positive and Negative Syndrome Scale (PANSS) subscale scores and side effects. An intention-to-treat analysis included all available observations, classified by initial drug assignment, and costs of reassignment of most patients to another second-generation drug. The analysis was repeated considering only treatment on initially assigned medications. RESULTS: Although QALY ratings, PANSS scores, and other quality of life measures indicated modest improvement over 18 months, there were no significant differences between perphenazine and any second-generation medication. Average total monthly health care costs were 300 dollars-600 dollars (20%-30%) lower for perphenazine than for second-generation antipsychotics because of lower drug cost. Differences in costs remained when maximally discounted drug prices were used for all patients and when only observations during treatment with the first medication were included. CONCLUSIONS: Treatment with perphenazine was less costly than treatment with second-generation antipsychotics with no significant differences in measures of effectiveness. However, the trial was limited by a high dropout rate, and longer-term neurological and metabolic side effects require further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tabachnick, B. G., & Fidell, L. S. (1983) · Cited by 80,032
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Smearing Estimate: A Nonparametric Retransformation Method
Duan, N. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10478017 · Cited by 2,232
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,790
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Stroup, T. S., McEvoy, J. P., Swartz, M. S., Byerly, M. J., Glick, I. D., Canive, J. M., McGee, M. F., Simpson, G. M., Stevens, M. C., & Lieberman, J. A. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006986 · Cited by 636
Self-citationA Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371202 · Cited by 516
Self-citationRosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Self-citationAtypical Antipsychotics and Parkinsonism
Rochon, P. A., Stukel, T. A., Sykora, K., Gill, S., Garfinkel, S., Anderson, G. M., Normand, S.-L. T., Mamdani, M., Lee, P. E., Li, P., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.16.1882 · Cited by 167
Cost-Effectiveness of Clozapine for Treatment-Resistant Schizophrenic Patients
Revicki, D. A., Luce, B. R., Weschler, J. M., Brown, R. E., & Adler, M. A. (1990) · Psychiatric Services · doi:10.1176/ps.41.8.850 · Cited by 116
Lenert, L. A. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.10.010 · Cited by 112
Do new prescription drugs pay for themselves?
Duggan, M. (2004) · Journal of Health Economics · doi:10.1016/j.jhealeco.2004.08.001 · Cited by 108
Essock, S. M., Frisman, L. K., Covell, N. H., & Hargreaves, W. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.987 · Cited by 85
Lee, P. E., Sykora, K., Gill, S. S., Mamdani, M., Marras, C., Anderson, G., Shulman, K., Stukel, T. A., Normand, S. T., & Rochon, P. A. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53418.x · Cited by 85
Nithsdale Schizophrenia Surveys 23: movement disorders
Halliday, J., Farrington, S. M., Macdonald, S., MacEwan, T., Sharkey, V., & McCreadie, R. G. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.181.5.422 · Cited by 79
Rosenheck, R., LESLIE, D. L., & Sernyak, M. J. (2001) · Medical Care · doi:10.1097/00005650-200103000-00010 · Cited by 65
Self-citationRosenheck, R. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.1.85 · Cited by 65
Self-citationReid, W. H., & Mason, M. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0408 · Cited by 28
Research works printed but not linked: 10
- Revicki DA, 1990, Hosp Community Psychiatry, 41, 850
- 10.2165/00019053-199915050-00005 · doi:10.2165/00019053-199915050-00005
- Jones PB, Markwick A
- First MB, 1995, Williams JBW: Structured Clinical Interview for DSM-IV Axis I and II Disorders, version 2.0
- Gold MR, 1996, Russell LB
- Drug Topics Red Book, 1999, Medical Economics Company
- Thompson Medstat Group, 2002, Marketscan Communical Claims and Encounters Database
- 10.1177/0272989X02239649 · doi:10.1177/0272989x02239649
- 10.1016/j.schres.2003.11.008 · doi:10.1016/j.schres.2003.11.008
- Daniels N, 2003, Sabin J: Setting Limits Fairly: Can We Learn to Share Medical Resources? New York
Cited by
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Kane, J. M., Robinson, D. G., Schooler, N. R., Mueser, K. T., Penn, D. L., Rosenheck, R. A., Addington, J., Brunette, M. F., Correll, C. U., Estroff, S. E., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15050632 · Cited by 857
Self-citationClaxton, K., Martin, S., Soares, M., Rice, N., Spackman, E., Hinde, S., Devlin, N., Smith, P. C., & Sculpher, M. (2015) · Health Technology Assessment · doi:10.3310/hta19140 · Cited by 853
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Self-citationCornblatt, B. A., Auther, A. M., Niendam, T., Smith, C. W., Zinberg, J., Bearden, C. E., & Cannon, T. D. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm029 · Cited by 630
Metadata
- Authors
- Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., Perkins, D. O., Hsiao, J. K., & Lieberman, J.
- Venue
- American Journal of Psychiatry
- Published
- 2006-12
- Volume
- 163
- Issue
- 12
- Pages
- 2080-2089
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2133198672
- Cited by
- 281
- References
- 22
- FWCI
- 21.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.